Prohibiting network exclusion for pharmacies that refuse to dispense a prescription of the PBM reimbursement that is below the pharmacy's acquisition cost.
The enactment of SB247 is expected to have a significant impact on state laws regarding pharmacy operations and consumer protection. By enabling pharmacies to refuse service based solely on reimbursement rates, the bill facilitates a more sustainable economic model for pharmacies. Furthermore, it sets a new standard for contracts between pharmacies and pharmacy services administrative organizations, ensuring they must comply with specific regulatory requirements. This move could result in increased transparency and might improve the negotiating power of pharmacies against large pharmacy benefit managers.
SB247 aims to prohibit network exclusion for pharmacies that choose not to dispense prescriptions when the reimbursement from a pharmacy benefits manager (PBM) is less than the pharmacy's acquisition cost. This legislation is particularly relevant as it seeks to empower pharmacies by allowing them the discretion to decline prescriptions based on the financial viability of fulfilling those prescriptions under existing contracts with PBMs. The bill, however, specifically excludes Medicaid and Medicaid care management from its provisions, indicating a targeted approach towards independent pharmacies operating outside Medicaid regulations.
The sentiment surrounding SB247 is generally supportive among pharmacy advocates, who view the bill as a necessary step toward ensuring fair reimbursement practices and economic sustainability for pharmacies. However, some concerns have arisen regarding the implications of this legislation for patient access to medications, as it could lead to potential delays in the dispensing of necessary prescriptions if pharmacies decline to fill them. The bill has sparked a robust dialogue about the balance between protecting pharmacy businesses and ensuring patient access to healthcare services.
Notably, the primary contention related to SB247 revolves around its exclusion of Medicaid from its provisions, which has raised questions about the broader implications for patients relying on Medicaid. Critics argue that this exclusion could undermine the accessibility of medications for low-income populations. Additionally, the potential increase in consumer protection claims against pharmacy services administrative organizations indicates that the legislation might lead to additional scrutiny and legal considerations that could impact how these entities operate in the future. Overall, the bill represents an intersection of business interests and patient care that remains a contentious issue.